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Focal segmental glomerulosclerosis (FSGS) is a kidney disease with progressive glomerular scarring and a clinical
presentation of nephrotic syndrome. FSGS is a common primary glomerular disorder that causes renal dysfunction
which progresses slowly over time to end-stage renal disease. Most cases of FSGS are idiopathic Although kidney
transplantation is a potentially curative treatment, 40% of patients have recurrence of FSGS after transplantation. In
this review a brief summary of the pathogenesis causing FSGS in humans is given, and a variety of animal models
used to study FSGS is discussed. These animal models include the reduction of renal mass by resecting 5/6 of the
kidney, reduction of renal mass due to systemic diseases such as hypertension, hyperlipidemia or SLE, drug-induced
FSGS using adriamycin, puromycin or streptozotocin, virus-induced FSGS, genetically-induced FSGS such as via
Mpv-17 inactivation and α-actinin 4 and podocin knockouts, and a model for circulating permeability factors. In
addition, an animal model that spontaneously develops FSGS is discussed. To date, there is no exact understanding
of the pathogenesis of idiopathic FSGS, and there is no definite curative treatment. One requirement facilitating
FSGS research is an animal model that resembles human FSGS. Most animal models induce secondary forms of
FSGS in an acute manner. The ideal animal model for primary FSGS, however, should mimic the human primary
form in that it develops spontaneously and has a slow chronic progression. Such models are currently not available.
We conclude that there is a need for a better animal model to investigate the pathogenesis and potential
treatment options of FSGS.
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Focal segmental glomerulosclerosis (FSGS) is a disease
with progressive glomerular scarring. Studies [1,2] have
shown that podocytes are the main cells involved in the
development of FSGS. Podocytes are epithelial cells of
the visceral layer of the kidney’s Bowman’s capsule. Their
function is to form a filtration structure that prevents
protein loss to the urine. Destruction of podocytes induced
by cellular stress results in sclerosis of part (segmental) of
the glomerular capillaries in a minority (focal) of glomeruli.
If the sclerosis continues, global glomerulosclerosis will
develop. Clinically, the loss of podocytes and their filtra-
tion function results in nephrotic syndrome, consisting* Correspondence: f.dor@erasmusmc.nl
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reproduction in any medium, provided the orof proteinuria, hypoalbuminemia, hypercholesterolemia
and peripheral edema [3].
FSGS has an incidence of 7 per million, and in 20% of
children and in 40% of adults, it is the underlying cause
of nephrotic syndrome. When FSGS is accompanied by
high proteinuria levels at the time of presentation, 50%
of cases progress to end-stage renal disease (ESRD) within
3 to 8 years, making FSGS causal for 4% of all ESRD cases
[3]. After kidney transplantation (KT) for primary FSGS,
the recurrence rate is 40% [4,5].
In 80% of FSGS patients, the etiology is unknown. In
the remaining 20% of cases, FSGS develops secondary to
other underlying diseases. Genetic causes (α-actinin 4
mutations) were found, as well as forms that were HIV
virus-associated, induced by drugs such as interferon-γ,
caused by a congenital reduction in renal mass (unilateral
agenesis) or by reduction of renal mass due to systemic
disease such as hypertension [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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1959 [7], many studies have been conducted to under-
stand its pathogenesis and to identify risk factors and/or
possible treatments for this disease. In order to facilitate
the study of FSGS, different kinds of animal models have
been developed to mimic the clinical pathological features
of human FSGS. In this review, we briefly summarize the
pathogenesis causing FSGS in humans, and subsequently
provide an overview of the different animal models that
are currently being used or have been used in the past to
investigate FSGS.
Pathogenesis of FSGS in humans
Secondary FSGS caused by systemic diseases
FSGS caused by systemic diseases such as hypertension,
diabetes and obesity will eventually lead to glomerular
hyperfiltration-hypertension, which causes mechanical stress
on the podocytes [8]. Mechanical stress leads to structural
changes in podocyte cell bodies and reinforces their ad-
herence to the glomerular basement membrane (GBM).
These changes are facilitated by angiotensin II (Ang II)-
and transforming growth factor beta (TGF-β) dependent
pathways. Ang II activation leads to generation of reactive
oxygen species, rearrangement of slit diaphragm pro-
teins, down regulation of nephrin expression and podocyte
hypertrophy. In addition, Ang II activates VEGF, which
leads to an increase in albumin uptake due to angiogenesis
and increased permeability of the capillary endothelium for
albumin. TGF-β down regulates α-3β-1 integrin expression,
which leads to foot process effacement and affects the
ability of podocytes to adhere to the GBM. Podocyte
hypertrophy, foot process effacement and detachment
from GBM eventually lead to apoptosis and podocyte
depletion. Diabetes can also directly activate the Ang II-
and TGF-β dependent pathways [8].
Drug-induced FSGS
Several drugs are able to induce FSGS. Pamidronate is
used for the treatment of myeloma and metastatic can-
cers. It has an inhibitory effect on actin cytoskeleton for-
mation in osteoclasts, and may have a similar effect on
the podocyte cytoskeleton. IFN-γ can affect podocytes
through the IFN-α and IFN-β receptors on podocytes. In
the transplanted kidney, FSGS may be induced by the
toxic effects of immunosuppressive drugs. For instance,
Rapamycin can induce FSGS by reducing the expression
of Nephrin and other proteins composing the slit dia-
phragm and cytoskeleton [9].
Virus-induced FSGS
Virus-induced FSGS can be caused by direct infection of
the podocyte or by the release of inflammatory cytokines
by other virus-infected cells that interact with podocyte
receptors. HIV-1 directly infects the podocytes and tubularepithelial cells. Viral genes such as Negative regulatory fac-
tor (Nef) and Viral protein R (Vpr) are causal for HIV-
associated nephropathy (HIVAN). Nef promotes podocyte
dedifferentiation and proliferation and dysregulation of
actin cytoskeleton. Vpr mediates tubular epithelial G2
cell-cycle arrest and apoptosis. HIVAN causes the col-
lapsing variant of FSGS [3].
Genetic defects causing FSGS
In familial FSGS several genetic defects have been dis-
covered, which account for 8% of FSGS causes [10]. The
affected genes encode important regulators of the actin
cytoskeleton of podocytes and form an extensive list of
factors. It includes Nephrin, a transmembrane protein
and an important structure of the slit diaphragm. Through
its cytoplasmic domain it regulates podocyte actin dynam-
ics [11]. Podocin is an adapter protein facilitating a func-
tioning filtration barrier by directing nephrin and CD2AP
to the right location in the slit diaphragm and therefore
connecting the slit diaphragm to the actin cytoskeleton
[12]. Besides being part of this connection, CD2AP also
helps maintaining the organization of the podocyte actin
cytoskeleton through regulation of cytosolic cathepsin L
expression [13]. α-Actinin-4 is an actin-binding protein
necessary for accurate regulation of actin turnover, im-
portant for maintaining a normal morphology and func-
tion of podocytes [14]. Transient receptor potential cation
channel 6 (TRPC6) is a calcium channel that is likely to
have an effect on the actin cytoskeleton through the
RhoA-pathway, a known modulator of the actin cyto-
skeleton [15]. In addition, TRPC6 combined with podocin
is thought to act as a mechanosensor at the slit diaphragm
by translating mechanical tension to ion-channel activity
[16]. Phospholipase C (PLC) ε1 is important for the de-
velopment and dedifferentiation of podocytes and inter-
action with nephrin through GTPase-activating protein
1. Its precise function in mature podocytes is however
unknown [17]. Inverted formin (INF) 2 is part of the
actin-regulating proteins inhibiting actin polymerization
via Rho/mDia-pathway [18]. Myosin 1E, a molecular motor
translocating cargo proteins along actin filaments, is im-
portant for podocyte migration and may also stabilize the
podocyte cytoskeleton [19]. ARHGAP24 is a gene necessary
for a normal functioning Rho-pathway, which, as men-
tioned before, is an important regulator of the actin cyto-
skeleton [20] (Figure 1). For a more detailed description
of these genetic defects, we recommend the following
reference [21].
Susceptibility genes
In addition to gene defects that have an immediate effect
on the podocyte cytoskeleton, polymorphisms in Myosin
heavy chain 9 (MYH9) and Apolipoprotein L1 (APOL1)
genes were identified that affect the susceptibility of
Figure 1 Regulators of the podocyte actin cytoskeleton and the
slit diaphragm.
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reorganization of the actin skeleton by replacing transver-
sal stress fibers with radial stress fibers connected to an
actin-rich centre [22]. It was found that hypertension
associated end-stage renal disease in African-Americans
is substantially related to both polymorphisms. MYH9
interacts statically with F-actin to maintain membrane
tension and cell shape and is therefore a likely candidate
to play a role in the development of FSGS. APOL1,
however, has a stronger association with FSGS than
MYH9 and could possibly be the actual susceptibility
gene [23].
Circulating permeability factors
The first speculations about the excistence of circulating
permeabillty factors date from 1972. Three cases of pa-
tients with steroid-resistant nephrotic syndrome were
described that progressed to ESRD within 2 to 6 years.
After receiving KT all 3 patients showed a recurrence
of nephrotic syndrome within 1 to 5 months. The kidneys
of 2 patients who died from immunological causes, were
studied. Both the native kidney as well as the allograft
showed FSGS in the juxtamedullary glomeruli, suggesting
a recurrence of the original disease in the transplanted
kidney. To explain these observations it was hypothesized
that systemic circulating factors might be involved [24].
Recently, a case was reported in which a primary FSGS
patient that received a kidney transplant developed marked
proteinuria on the second day post transplantation. A
biopsy demonstrated recurrence of the disease despite
plasmapheresis. On day 14 the allograft was removed
due to worsening of the disease. The removed kidney
was then retranspanted into a patient with ESRD caused
by type 2 diabetes. After transplantation the kidney
regained function and biopsy analysis showed a reversal
of the histopathological lesions. This case supports thecirculating permeability factor theory and that podocyte
injury may be reversible before scar formation occurs
[25]. In a different study researchers observed that there
was an increase in glomerular permeability for albumin
when rat glomeruli were exposed to serum samples from
FSGS patients. This effect was even more pronounced
when serum was used from patients with recurrent disease
after transplantation. In addition, glomeruli were exposed
to serum from patients with recurrent FSGS after plasma-
pheresis as well as the plasmapheresis fluid that was
gained from these patients. The serum reduced protein-
uria whereas the plasmapheresis fluid showed an increase.
These findings proved the circulating factor to be pri-
marily confined to the plasma space and not rapidly
synthesized after plasmapheresis [26]. The most likely
candidate representing the responsible circulating factor
is soluble urokinase-type plasminogen activator receptor
(suPAR). Significantly elevated suPAR concentrations are
observed in patients with primary and recurrent FSGS.
High pre-KT suPAR concentrations significantly increase
the risk for recurrence of FSGS in the allograft. 1 year
post-KT elevated concentrations are observed in patients
with recurrence of FSGS compared to non-recurrence
in patients. Physiologically low concentrations of suPAR
are involved in neutrophil trafficking and stem cell
mobilization. In podocytes high concentrations of suPAR
can pathologically activate β3 integrin. β3 integrin plays an
important role in anchoring podocytes to the glomerular
basement membrane and the development of mature foot
processes. Activation leads to foot process effacement,
proteinuria and initiation of FSGS. SuPAR concentrations
can be lowered by plasmapheresis, which decreases β3
integrin activity. This study shows suPAR to be a circulat-
ing factor that can cause primary and recurrent FSGS and
an important measurable risk factor for recurrent disease
[27]. Another possible circulating factor is Cardiotrophin-
like cytokine 1, however this candidate awaits further
study [3].
Animal models for FSGS
As described above, the various suggested causes for FSGS
in humans all target podocytes. Damaging of podocytes
leads to foot process effacement and eventually detach-
ment from the GBM. Adhesions are formed between the
denuded GBM and Bowman’s capsule, and parietal epi-
thelial cells (PEC) start producing extracellular matrix
(ECM), which causes the typical FSGS lesions [3]. Animal
models used to investigate FSGS all induce damage to
podocytes and thereby mimic human FSGS.
Remnant kidney model
The most frequently used animal model for FSGS is the
reduced or remnant kidney model in rats. In this model,
4/6 or 5/6 of renal mass is removed by surgically resecting
de Mik et al. BMC Nephrology 2013, 14:74 Page 4 of 10
http://www.biomedcentral.com/1471-2369/14/74one kidney and ligation of renal artery branches or
polectomies to reduce one or two thirds of the renal mass
in the contralateral kidney [28]. Most studies use the 5/6
ablation model, since it induces hypertension, pronounced
renal damage and FSGS. The 4/6 renal mass reduction
model is used as a milder variant since it does not induce
hypertension, and only moderate renal dysfunction and
glomerulosclerosis [29,30].
To compensate for the loss of renal mass, tubular and
glomerular growth occurs. Glomerular growth is achieved
by both hyperplasia and hypertrophy. Podocyte growth is
structurally slower, as it occurs only through hypertrophy.
Therefore, both the capillary and filtration area for a
single podocyte is dramatically enlarged. As a consequence,
the filtrate cannot be filtered into the urinary space fast
enough, causing blockages which divert the filtrate into the
space between the podocyte body and foot processes. These
maladaptive changes eventually lead to cell destruction
and adhesions between the GBM and Bowman’s capsule
leading to sclerosis [31]. In addition, studies using polectomy
models show only moderate hypertension and slow devel-
opment of glomerulosclerosis. This is in contrast with
ligation models which cause more pronounced hyper-
tension. The presence of hypertension and a rapid de-
velopment of glomerulosclerosis is caused by the marked
up-regulation of components of the renin angiotensin sys-
tem, namely Ang II, in the inflamed peri-infarct zone in
ligation models, leading to structural changes in podocytes
[32]. The remnant kidney model can cause podocyte dam-
age through both hyperfiltration-hypertension and via the
Ang II pathway, similar to what is seen in human FSGS.
Most rat strains are susceptible to induction of FSGS
via the remnant kidney model. Munich-Wistar rats have
the benefit of having surface glomeruli that can be used
for direct measurement of hemodynamic factors. In
contrast, most mouse strains, including C57BL/6, are
resistant to the development of FSGS via the remnant
kidney model. 129Sv mice are susceptible but the anatomic
distribution of the renal artery branches in mice makes it
difficult to achieve reproducible 5/6 nephrectomy [28].
There also seems to be a gender-dependent difference in
the susceptibility to FSGS. Studies using the remnant kid-
ney model in Munich-Wistar rats and Sprague–Dawley
rats have shown that estrogens, mainly estradiol, can pro-
tect against FSGS development [33,34].
Studies using the remnant kidney model are conducted
for the development of preventive treatment strategies as
well as for gaining more insight in underlying patholo-
gies. Using this model it was found that inhibition of
thromboxane synthesis [35], the administration of clofibric
acid (lipid-lowering agent) [36], troglitazone (peroxisome
proliferator-activated receptor-gamma agonist) [37] and
Tranilast (antifibrotic agent) [38] can all ameliorate pro-
gressive glomerulosclerosis. These studies [35]- [38] allused Sprague–Dawley rats of either male or female sex
and reduced renal mass via the renal artery branch
ligation technique. Other studies show that absence of
functional p21(WAF1/CIP1) in the 129/Sv mouse strain
can reduce progression to chronic renal failure [39] and
that apolipoprotein E knockout mice do not have an in-
crease in renal injury after subtotal nephrectomy in the
presence of hyperlipidemia [40], suggesting a role for
this protein in the development of secondary FSGS. Both
studies [39,40] used polectomies to induce the remnant
kidney model.
The remnant kidney model is limited in its abilities to
mimic human FSGS, since the damage is induced via an
acute procedure, whereas in human FSGS the damage is
induced much slower. However, the remnant kidney model
can be used in combination with other FSGS inducing mo-
dalities, such as injections with puromycin or with induced
hypertension. These FSGS models will be discussed in the
next paragraphs.Renal mass reduction due to systemic disease
The reduction of renal mass is a secondary event to cer-
tain pathologies. In a number of animal models, the de-
crease in renal mass is the result of chronic damage to the
glomerular vessels due to hypertension. In these models,
FSGS develops in a similar fashion as in the remnant kid-
ney model, where a decrease in renal mass leads to the
availability of a reduced number of glomeruli to filtrate
the same amount of serum. Techniques to study hyperten-
sion include the use of Sabra hypertension prone rats,
which are salt-sensitive animals that develop hypertension
when chow and tap water are loaded with 8% NaCl [41].
Renal hypertension can furthermore be caused by admin-
istration of norepinephrine (NE) or Ang II. In this model
Male Sprague- Dawley rats are used, which are given NE
and Ang II intravenously for 14 days, while an inflatable
vascular occluder maintains renal perfusion pressure to
the left kidney at baseline levels, and exposes the right kid-
ney to elevated perfusion pressure [42]. In addition, hyper-
lipidemia and obesity models such as Zucker rats have
been investigated [43] as well as the ageing, the nephron
deficient Munich-Wistar Frömter rat [44].
Besides observing the effect of hypertension on the
development of glomerulosclerosis in these two animal
models, the Zucker rats show that early influx of glom-
erular macrophages precedes glomerulosclerosis [43].
The aging Munich-Wistar rats show that age-dependent
glomerulosclerosis is reversed after endothelin-1 inhib-
ition. Endothelin-1 seems to have an inhibitory effect on
podocyte cell-cycle activity and dedifferentiation. When
administering an endothelin-1 antagonist podocytes may
re-enter the cell-cycle and recover from previous and age-
related injury [45].
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anti-phospholipid antibodies present in systemic lupus
erythematosus (SLE) that occlude the glomerular vessels
and result in chronic inflammation. This chronic inflam-
mation is thought to cause hypertension similar to what
is described in the remnant kidney model using ligation.
Female NZBWF1 mice are known to produce high titers
of antinuclear antibodies. In these mice the kidney is
protected from damage by TNF-α blockade [46].
These animal models are all good representations of
secondary FSGS in humans. Unfortunately secondary FSGS
is only a small part of human FSGS and development to
FSGS can often be prevented and/or delayed by treatment
of these underlying causes.Drug-induced
Adriamycin, puromycin, and streptozotocin are the drugs
mostly used to induce FSGS. Additionally, available litera-
ture describes a small number of studies conducted with
cyclosporine [47] and growth hormone [48], which will
not be discussed here.
Most rat strains are susceptible to FSGS induced by
adriamycin or puromycin. Most mice strains are not, ex-
cept for balb/c mice, which are susceptible to adriamycin
induced FSGS [28].
Adriamycin is known as an oncolytic antibiotic that can
induce proteinuria from the second infusion onward,
when given intravenously in rats at 2 mg/kg in a 3-week
interval. After 16 weeks, segmental glomerulosclerosis
is observed with progression to global glomerulosclerosis
and tubulointerstitial fibrosis at 24 weeks. Due to in-
creased serum urea levels, some of the animals will not
survive beyond 28 weeks. When given in a single intraven-
ous dose of 5 mg/kg, adriamycin causes sclerosis within
6 months in 50% of animals [49]. Studies that will be
discussed used male Munich-Wister rats and injected a
single dose. The given doses range from 1,5 to 5 mg/kg
in rats [49,50] and 10 to 15 mg/kg in mice [51]. It is im-
portant to test the dose before conducting experiments
since adriamycin has a small pharmaceutical range, out-
side of which it becomes toxic. In addition, batch differ-
ences can be observed [50].
Puromycin is an antibiotic that inhibits protein synthe-
sis. Puromycin can be given by multiple intraperitoneal
injections with initial administration of 10 mg/kg followed
by 40 mg/kg every 4 weeks or as a single intravenous dose
of 50 mg/kg to cause puromycin aminonucleoside-induced
nephrosis (PAN). After injection, rats show an early neph-
rotic phase peaking at 10 days with complete foot process-
effacement followed by apparent resolution. Between 10
and 13 weeks, progressive lower-level proteinuria develops
with early segmental sclerotic lesions leading to well-defined
segmental sclerosis at 18 weeks [52].Both adriamycin and puromycin are used frequently to
induce FSGS because of their strong dose–response ef-
fects [28]. These drugs are often used in the same study
in two separate arms. These models have been used to
study serial micropuncture analysis of a single nephron
while glomerulosclerosis is developing [53]. FSGS treat-
ment studies for which adriamycin and puromycin animal
models are used show that the combination of Angiotensin
converting enzyme-inhibitors (ACE-I) and Ang II blockers
do not have a better effect than ACE-I alone [54]. In
addition, they show that MAPK is essential for podocyte
injury making p38 MAPK a potential therapeutic target
[55] and that vaccination with CCL2 DNA protects against
kidney injury after adriamycin injections [56]. Possible new
biomarkers for initiation and severity of FSGS, such as
fibronectin [57] and Rab-23 [58] respectively, were stud-
ied in these animal models as well. Serum fibronectin
levels can show a slight but significant increase 3 days
before the occurrence of glomerular fibronectin deposits
making it a non-specific biomarker for predisposition of
FSGS [57]. In case of Rab-23, an autocrine signaling path-
way is observed in mesangial cells while developing FSGS,
which leads to elevated urine levels of Rab-23 and sup-
presses this pathway. Therefore, as a biomarker, Rab-23
urine levels may perhaps indicate the severity of FSGS [58].
Both drugs cause direct toxic damage to the podocytes,
increase the permeability of glomerular endothelial cells
for larger molecules, and reduce glomerular charge select-
ivity, which leads to tubulointerstitial injury [50]. Since
these pathways are different than those known in human
FSGS, the relevance of these models is unclear.
Streptozotocin is a naturally occurring chemical, which
is toxic to insulin-producing beta-cells of the pan-
creas. It can be used to treat cancers of the Islets of
Langerhans [59] and in medical research to induce dia-
betes in animal models [60]. The diabetic nephropathy
induced in this model precedes the development to
FSGS. Intraperitoneal injection of 40 mg/kg in male
Syrian APA hamsters induces an ongoing hypergly-
cemia and hyperlipidemia with high glucose urine
levels, which results in glomerular lipidosis after 1 month.
After 3 months, FSGS with mesangial expansion is seen.
This is caused by an increase of basement membrane-
like material, lipid droplets and foam cells. Especially
the hyperlipidemia is crucial in this development since
it forms the lipid droplets [61].
Studies using streptozotocin-induced hyperglycemia
in male Munich Wistar rats show that doxazin, a blood
pressure lowering agent, reduces albuminuria by 80%,
but does not have an effect on mesangial expansion or
progression to glomerulosclerosis. In contrast, proper gly-
cemic control prevents all three [60]. Altered gene ex-
pression in the early phase of kidney disease caused by
hyperglycemia may be critical in these animals [62].
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Virus induced animal models that are most often used
in FSGS research are HIV-1 based models, in which
transgenic mice express HIV-1 accessory genes such as
Vpr [63]. These transgenic mice are obtained either by
transfecting fertilized eggs of a hybrid between C57BL/6
and DBA/2 with Vpr and the nephrin gene promoter
[63] or by using the Tg26 mouse line [64]. In addition,
rhesus macaques infected with SIVmacR71/17E, a cloned
lymphocyte tropic simian immunodeficiency virus (SIVAN),
are used to study FSGS [65]. As mentioned above the virus
can inflict damage on podocytes, either by direct infection
of these cells or by the release of inflammatory cytokines.
Furthermore the virus can transfer from infected T-cells
to tubular epithelial cells via viral synapses during cell
adhesion [66]. Studies using this animal model have dem-
onstrated protection and reversal of glomerulosclerosis by
treatment with Fluvastatin [64] and the cyclin-dependent
kinase inhibitor CYC202 [67] respectively.
These animal models are important to study HIVAN
since human renal cells also express HIV-1 genes. How-
ever, HIVAN is a secondary cause of FSGS and does not
widen our knowledge of primary FSGS.
Podocyte targeting models of FSGS
Since podocytes were identified as the major cellular target
in FSGS, new animal models were developed. Genes
encoding for podocyte-specific proteins were targeted
to obtain knockout mouse models for FSGS. Mpv-17
and α -actinin 4 were the genes targeted most frequently.
Podocin deficient mice will be discussed, as well as deple-
tion of podocytes by Thy-1.1 antibody and diphtheria toxin.
Mpv-17 inactivation by retroviral insertion results in
foot process flattening and proteinuria within 30 days
postpartum, caused by an excessive production of oxy-
gen radicals, and accumulation of lipid peroxidation ad-
ducts. After 9–12 months the mice succumb to kidney
failure [68].
Studies using Mpv-17 inactivation show depletion of
mitochondrial DNA which affects skin, inner ear and
kidney. At the onset of FSGS, hardly any mitochondrial
DNA is left in the cells of the glomerular tuft [69].
The α-actinin 4 gene encodes for the production of an
actin cross-linking protein. Point mutations in this gene
cause an autosomal dominant form of human FSGS.
There is significant reduction of mRNA and nephrin, a
component of the slit diaphragm. The result is a rapidly
degrading and deregulated actin cytoskeleton (caused by
α-actinin-4) and deterioration of the slit diaphragm (caused
by nephrin), leading to early development of proteinuria
and FSGS [70]. In studies with α-actinin 4 mutated mice,
samples are used for comparison with the autosomal dom-
inant form of human FSGS caused by the same α-actinin 4
mutation [70].Podocin is encoded by the NPHS2 gene. Mutations in
this gene cause familial and sporadic forms of steroid-
resistant nephrotic syndrome and FSGS in humans.
NPHS2 knockout mice do not develop FSGS, but diffuse
mesangial sclerosis. These mice die within days to weeks
after birth from renal failure [71]. However, when podocin
is inactivated in adult mice by using Cre-loxP technology,
it results in nephritic syndrome and FSGS within 4 weeks.
This is followed by diffuse glomerulosclerosis and tubulo-
interstitial injury [72].
An inducible model for FSGS has been generated by
introducing the expression of the Thy-1.1 antigen on
podocytes. Thy-1.1 is not expressed on podocytes in nor-
mal mice. The mouse model was developed by injecting
human-mouse Thy-1.1 in zygotes of Thy-1.2 CBA x
C57BI mice. After injecting anti-Thy-1.1 monoclonal anti-
bodies, podocytes and parietal epithelial cells (PEC) are
damaged leading to podocyte hypertrophy and extracellu-
lar matrix production by PEC [73]. Acute albuminuria is
induced within a day, and is accompanied by a rapidly
developing focal glomerulosclerosis at day 21. The Thy-1.1
transgenic mouse model is appropriate to specifically
study the relation between podocyte injury, albuminuria
and FSGS development, since it has been proven that in
this model the severity of FSGS correlates with the ex-
tend of podocyte injury [74]. In this model, it has also
been demonstrated that ACE-I is important in preventing
development of FSGS, possibly through PEC proliferation
blockage [75].
Inducing FSGS in transgenic animals via injection of
podocyte-specific toxins was also accomplished by devel-
oping rats that express human diphtheria toxin receptors
(hDTR) on podocytes. Fertilized Fisher rats were injected
with podocin promoter/hDTR to develop these transgenic
mice. After reaching adult age, the rats were injected with
diphtheria toxin (DT, 1 ml/10 g) causing depletion of
podocytes that transport DT into their cytoplasm within
7 days. When 20% of podocytes are lost, mesangial ex-
pansion and mild proteinuria develop without loss of
kidney function, which suggests that a compensatory
mechanism is induced. After depletion of 40% of the
podocytes, synechia formation, moderate proteinuria and
FSGS lesions including GBM adhesions, PEC migration
and ECM formation start to develop. When more than
40% of podocytes are depleted, global sclerosis develops [2].
These models all affect podocytes, either by targeting
existing genes and their encoding proteins, or by the
transfection of specific receptors on podocytes, which
can specifically be targeted. The models using existing
genes cover less than 8% of human causes for FSGS.
Both podocyte depletion models give important informa-
tion about the continuous progression of FSGS in a dose
dependent manner, but do not address the cause of pri-
mary FSGS.
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Animal studies have helped to prove the existence of cir-
culating permeability factors causal for FSGS by showing
that FSGS can be induced in rats after injection with
serum of FSGS patients. Both studies discussed here used
Sprague–Dawley rats that were injected with serum of
biopsy-proven FSGS in patients with primary disease.
These studies show that a single injection of FSGS patient
serum causes transient albuminuria and proteinuria in rats
[77] and that especially serum from patients with the col-
lapsing FSGS variant leads to glomerular tuft retraction
and podocyte damage [76].Table 1 Overview of animal models discussed in this review
Animal models Method of develop
Remnant kidney model [28-34] 5/6 renal mass resect
Renal mass reduction due to systemic disease [41,44] Salt sensitive animals
Norepinephrine
Angiotensin
Zucker rats
Munich Wistar rats
SLE
Drug-induced [28,49-52] Adriamycin Puromyc
Streptozotocin
Virus-induced [63-65] Vpr-gene
SIVAN
Genetic targets [2,68,70,71,73] Mpv-17
α-actinin 4
Podocin-deficiency
Thy-1.
hDTR
Circulating permeability factors [76,77] Collapsing variant se
Supernatant injection
Spontaneously [78] Accidental
Abbreviations: SLE, Systemic lupus erythematosus; TNF- α, Tumor necrosis factor-alf
Mitogen-activated protein kinases; CCL2, Chemokine (C-C motif) ligand 2; Vpr, Viral
DNA, Deoxyribonucleic acid; FSGS, Focal segmental glomerulosclerosis; hDTR, huma
Quantitative trait loci.To date, there is no consensus on which candidate factor
the actual “FSGS-factor” is or where it is produced. These
studies support the existence of a circulating permeability
factor, and have the potential to identify this “FSGS-
inducing factor”.
Spontaneously developing FSGS
In the literature, only one spontaneously developing FSGS
mouse model has been published. Studies using this FGS/
Nga mouse model have appeared between 1991 and 2004.
The mouse model was established after interstrain cross-
breeding of CBA/Nga and RFM/Nga offspring. The straining Examples of FSGS research conducted using
these animal models
ion Use of thromboxane inhibitors [35]
Use of lipid lowering agents [36]
Use of peroxisome proliferator [37]
Use of antifibrotic agents [38]
Absence of p21 [39]
Absence of Apolipoprotein E [40]
Role of hypertension [41,42]
Role of macrophage influx [43]
Use of Endothelin-1 inhibition [44,45]
Use of TNF-α blockade [46]
in Use of ACE-I + Ang II inhibitors [54]
Role of MAPK [55]
Use of CCL2 vaccination [56]
Role of fibronectin as biomarker [57]
Role of Rab 23 as biomarker [58]
Role of good glycemic versus blood pressure control [60]
Use of fluvastatin [64]
Use of CYC202 [67]
[65]
Role of mitochondrial DNA [69]
Genetic human FSGS comparison [70]
Knockout versus depletion [71,72]
Role of ACE-I [75]
Presence of threshold [2]
rum injection Podocyte damage after injection [76]
Induction of transient proteinuria [77]
Use of BMT [79]
Role of QTL [80]
a; ACE-I, Angiotensin-converting-enzyme inhibitor; Ang II, Angiotensin II; MAPK,
protein R; SIVAN, Simian immunodeficiency virus associated nephropathy;
n diphtheria toxin receptor; BMT, Bone marrow transplantation; QTL,
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severe glomerulosclerosis within one year. Studies of this
mouse model revealed dense deposits in the mesangium
containing IgA, IgM, C3 and the retroviral envelope
antigen. Breeding of these animals was possible up to 18
generations [78].
A study using this mouse model showed that bone mar-
row transplantation (BMT) from normal mice to FSGS
mice ameliorates FSGS and that BMT or transfer of puri-
fied hematopoietic stem cells from FSGS mice to normal
mice induced FSGS [79]. A study was conducted to locate
quantitative trait loci (QTL) affecting the glomerulosclerosis
index (GSI) in these mice. Two QTL were found on chro-
mosomes 8 and 10. The presence of Gsi1 increased the GSI
while the presence of Gsi2 decreased GSI [80].
Currently, only some embryos of this mouse model are
left in Japan, but no active research seems to be performed
[78] (Table 1).
Review and conclusions
Much of our knowledge on FSGS has come from a var-
iety of animal models. However, to date, there is still no
exact understanding of the pathogenesis of idiopathic
FSGS, and there is no definite curative treatment. There-
fore, more research on FSGS is necessary. Although kid-
ney transplantation is currently the best treatment option,
the donor shortage, the high posttransplant FSGS recur-
rence rate, and the side effects of immunosuppression, all
warrant improvement of treatment. Our inability to fully
understand the pathogenesis and find curative treatment
for FSGS may be due to the fact that almost all of the ani-
mal models used are based on the induction of secondary
forms of FSGS. Most of them show an acute onset of pro-
teinuria and FSGS, whereas in human FSGS 80% is idio-
pathic and develops as a chronic disease over time. Future
FSGS research requires an animal model that resembles
human primary FSGS in that it has a spontaneous onset
and shows slow chronic deterioration. Such a model is
currently lacking.
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